Marisa Wexler, MS,  senior science writer—

Step count and heart rate data from wearable sensors can be of use as real-world approximations of common clinical tests of fitness, a study drawing on data from people with pulmonary arterial hypertension (PAH) shows. “Activity tracker-measured health parameters could serve as proxies for clinically measured health parameters of…

The experimental therapy HS135 improved heart function and the remodeling of lung blood vessels in a rat model of pulmonary hypertension (PH). That’s according to data reported by the therapy’s developer, 35Pharma, at the 2022 American Heart Association Scientific Sessions (AHA 2022), held earlier this month in Chicago…

Premature newborns who are treated for eye problems with anti-VEGF therapies may be at increased risk of developing pulmonary hypertension, a new study suggests. “Future studies evaluating the safety of anti-VEGF therapy should include pulmonary hypertension as a key clinical outcome. This is especially important as anti-VEGF treatment usage…

The U.S. Food and Drug Administration (FDA) granted breakthrough device designation to the CorVista System, a point-of-care diagnostic tool that aims to use non-invasive tests and machine learning to help diagnose pulmonary hypertension and other cardiovascular disorders. The designation gives CorVista Health, the system’s developer, certain benefits aimed…

Switching from weekly infusions of levosimendan to a daily oral version of the experimental medication was well-tolerated among people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), according to new trial data. That data, from the open-label extension phase of the HELP Phase 2 clinical…

Treatment with sotatercept, given in addition to standard therapies, significantly improves exercise capacity in people with pulmonary arterial hypertension (PAH). Those are the new findings of a pivotal Phase 3 clinical trial called STELLAR, which tested the therapy’s safety and efficacy in improving PAH patients’ ability to walk. Now,…

Two weeks of aerobic exercise improved blood flow parameters and survival in a rat model of pulmonary arterial hypertension (PAH), and altered the energy usage of cells in the heart, a new study reports. “Our data support the beneficial effect of exercise training in this clinical setting, as two…

A high dose of Tyvaso (inhaled treprostinil) — at least nine breaths four times per day — is more effective at preventing clinical worsening than lower doses for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), a new study indicates. “This analysis further reinforces that [Tyvaso]…

The U.S. Food and Drug Administration (FDA) has accepted a proposal from Bellerophon Therapeutics to reduce the size of a Phase 3 clinical trial that’s testing its INOpulse device on people with pulmonary fibrosis (PF) at risk of pulmonary hypertension (PH). The change, made based on analyses from…

Treatment with Pulnovo Medical‘s pulmonary artery denervation (PADN) device improved exercise capacity, blood flow dynamics, and clinical outcomes for pulmonary arterial hypertension (PAH) patients in a clinical trial called PADN-CFDA, the company announced. “The PADN-CFDA results are very important because this was an adequately powered randomized controlled trial,…

Mice that lack a protein called AMPK in the muscle around their blood vessels develop a lethal disease that appears very similar to persistent pulmonary hypertension of the newborn (PPHN), suggesting that AMPK may be a useful therapeutic target in this disease, according to a new study. “This study…

Scores on standardized risk assessments showed a clear treatment effect with Orenitram (treprostinil) after three months in a pulmonary arterial hypertension (PAH) clinical trial, with patients showing risk score improvements being less likely to have clinical worsening later on. The results of this new analysis suggest early changes…